Association between Pulmonary Aspergillosis and Cytomegalovirus Reactivation in Critically ill COVID-19 Patients: A Prospective Observational Cohort Study
Authors:
- Valeria CaciagliVCValeria Caciagli
- Irene ColorettiICIrene Coloretti
- Marta TalamontiMTMarta Talamonti
- Carlotta FarinelliCFCarlotta Farinelli
- Ilenia GattoIGIlenia Gatto
- Emanuela BiagioniEBEmanuela Biagioni
- Mario SartiMSMario Sarti
- Erica FranceschiniEFErica Franceschini
- Marianna MeschiariMMMarianna Meschiari
- Cristina MussiniCMCristina Mussini
- Roberto TonelliRTRoberto Tonelli
- Enrico CliniEnrico Clini
Preprint
- 13 October 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Introduction and Aims: COVID-19-associated invasive pulmonary aspergillosis (CAPA) is common and is associated with poor outcomes in critically ill patients. This prospective observational study aimed to explore the association between CAPA development and the incidence and prognosis of cytomegalovirus (CMV) reactivation in critically ill COVID-19 patients. Materials and Methods: We included all consecutive critically ill adult patients with confirmed COVID-19 infection who were admitted to three COVID-19 intensive care units (ICUs) in an Italian hospital from February 25, 2020, to May 8, 2022. A standardized procedure was employed for early detection of CAPA. Risk factors associated with CAPA and CMV reactivation and the association between CMV recurrence and mortality were estimated using adjusted Cox proportional hazard regression models. Results: CAPA occurred in 96 patients (16,6%) of the 579 patients analyzed. Among the CAPA population 40 (41,7%) patients developed CMV blood reactivation with a median time of 18 days (IQR 7-27). The CAPA+CMV group did not exhibit a significantly higher 90-day mortality rate (62.5% vs. 48.2%) than the CAPA alone group (p=0.166). The CAPA+CMV group had a longer ICU stay, fewer ventilation-free days, and a higher rate of secondary bacterial infections than the control group of CAPA alone. In the CAPA population, prior immunosuppression was the only independent risk factor for CMV reactivation (HR 2.33, 95% C.I. 1.21-4.48, p=0.011). Conclusions: In critically ill COVID-19 patients, CMV reactivation is common in those with a previous CAPA diagnosis. Basal immunosuppression before COVID-19 appeared to be the primary independent variable affecting CMV reactivation in patients with CAPA. Furthermore, the association of CAPA+CMV versus CAPA alone appears to impact ICU length of stay and secondary bacterial infections but not mortality.Keywords
All Related Versions
- Version 1, 2023-10-13, Preprints
- Published version: Viruses, 15 (11), 2260.
This publication has 20 references indexed in Scilit:
- Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortalityIntensive Care Medicine, 2022
- Invasive pulmonary aspergillosis is associated with cytomegalovirus viremia in critically ill patients - A retrospective cohort studyJournal of Microbiology, Immunology and Infection, 2022
- COVID-19-Associated Pulmonary Aspergillosis (CAPA)Journal of Intensive Medicine, 2021
- Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidanceThe Lancet Infectious Diseases, 2021
- Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)Clinical Microbiology and Infection, 2021
- Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinionIntensive Care Medicine, 2020
- Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research ConsortiumClinical Infectious Diseases, 2019
- Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort studyThe Lancet Respiratory Medicine, 2018
- IDSA Guidelines for the Diagnosis and Management of Intravascular Catheter‐Related Bloodstream InfectionClinical Infectious Diseases, 2009
- Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patientsBone Marrow Transplantation, 2009